Trivorin is an azole antifungal, indicated for the treatment of:
< lnvasive aspergillosis
< Candidemia (nonneutropenics) and disseminated candidiasis in skin, abdomen, kidney, bladder wall and wounds
< Esophageal candidiasis
< Serious infections caused by Scedosporium Apiospermum and Fusarium species including Fusarium Solani, in patients intolerant of, refractory to or other therapy

Trivorin tablet are to be taken at least one hour before or one hour following a meal:
< At or over 40 Kg body weight loading dose regimen is 400 mg every 12 hours (for
the first 24 hours) and maintenance dose (after first 24 hours) is 200 mg twice daily.
< Below 40 Kg body weight loading dose regimen is 200 mg every 12 hours (for the
first 24 hours) and maintenance dose (after first 24 hours) is 100 mg twice daily.
< Hepatic impairment: Use half of maintenance dose in patients with mild to
moderate hepatic impairment (Child-Pugh Class A and B).

< CYP3A4, CYP2C9 and CYP2C19 inhibitors and inducers: Adjust voriconazole
dosage and monitor for adverse reactions or lack of efficacy.
< Voriconazole may increases the concentrations and activity of drugs that are
CYP3A4, CYP2C9 and CYP2C19 substrates. Reduce dosage of these drugs and
monitor for adverse reactions.
< Phenytoin or Efavirenz: with co-administration, increase maintenance oral and
intravenous dosage of voriconazole.

< Pediatrics: Safety/effectiveness in patients <12 years has not been established.
< Hypersensitivity to voriconazole or its excipients.
< Co-administration with terfenadine, astemizole, cisapride, pimozide or quinidine, sirolimus due to risk of serious adverse reactions.
< Co-administration with rifampin, carbamazepine, long-acting barbiturates,   
  efavirenz, ritonavir, rifabutin, ergot alkaloids and St. John's Wort due to risk of loss of efficacy.

Most common adverse reactions (incidence>2%): visual disturbances, fever, nausea, rash, vomiting, chills, headache, liver function test abnormality, tachycardia and hallucinations.

< Pregnancy: Voriconazole can cause fetal harm when administered to pregnant woman. lnform pregnant women about the risk to the fetus.

< Store at 150C to 300C & dry place, protected from light.
< Keep out of reach of children.